梅州咨询处女膜修复术梅州眼袋内切,梅州怀孕多久能打胎,梅州处女膜 修补 手术,梅州妇科附件炎影响怀孕吗,梅州盆腔炎的原因是什么,梅州盆腔炎哪家医院比较好,梅州怀孕多少天能做打胎

WASHINGTON, June 21 (Xinhua) -- A new study from Harvard School of Public Health (HSPH) and University of California, San Francisco, researchers suggests that men with prostate cancer who smoke increase their risk of prostate cancer recurrence and of dying from the disease. The study will be published Wednesday in the Journal of the American Medical Association."In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said Stacey Kenfield, lead author and a research associate in the HSPH Department of Epidemiology. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."Kenfield and her colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32 percent) due to prostate cancer, 416 (26 percent) due to cardiovascular disease, and 878 prostate cancer recurrences.The researchers found that men with prostate cancer who were current smokers had a 61 percent increased risk of dying from prostate cancer, and a 61 percent higher risk of recurrence compared with men who never smoked. Smoking was associated with a more aggressive disease at diagnosis, defined as a higher clinical stage or Gleason grade (a measure of prostate cancer severity). However, among men with non-metastatic disease at diagnosis, current smokers had an 80 percent increased risk of dying from prostate cancer.Compared with current smokers, men with prostate cancer who had quit smoking for 10 or more years, or who had quit for less than 10 years but smoked less than 20 pack-years before diagnosis, had prostate cancer mortality risk similar to men who had never smoked. Men who had quit smoking for less than 10 years and had smoked 20 or more pack-years had risks similar to current smokers."These data are exciting because there are few known ways for a man to reduce his risk of dying from prostate cancer," said senior author Edward Giovannucci, professor of nutrition and epidemiology at HSPH. "For smokers, quitting can impact their risk of dying from prostate cancer. This is another reason to not smoke."Prostate cancer is the most frequently diagnosed form of cancer diagnosed in the United States and the second leading cause of cancer death among U.S. men, affecting one in six men during their lifetime. More than two million men in the U.S. and 16 million men worldwide are prostate cancer survivors.

BEIJING, Sept. 1 (Xinhua) -- Chinese scientists have decided to reschedule the launch of the Tiangong-1, an unmanned space module, due to the failed launch of an experimental orbiter, a spokesperson with the project said Thursday.The decision to delay the launch was based on the consideration that the carrier rocket Long-March II-F, which would be used for the upcoming launch, belongs to the same series as the malfunctioning one that led to the experimental orbiter SJ-11-04 failing to enter Earth's orbit in August."As the investigation into the malfunction of the rocket Long-March II-C remains underway, it is not clear yet whether the malfunction is linked with the Long-March II-F," the unnamed spokesperson said.Previously, the Long-March II-F was expected to send the 8.5-metric ton Tiangong-1, or "Heavenly Palace 1," into space in the second half of this year to perform the nation's first space-docking procedure.The Tiangong-1 will dock with the unmanned Shenzhou-8 spacecraft, which will be sent into space after the Tiangong-1's launch."The specific launch date for the Tiangong-1 will be set based on the results of the investigation into the malfunctioning rocket," the spokesperson said, adding that the project's teams are currently double-checking every product that will be involved in the space-docking.The Shenzhou-8 spacecraft, the Long March II-F carrier rocket, and the Tiangong-1 have all been transferred to the Jiuquan Satellite Launch Center in northwest China's Gansu Province, the spokesperson said.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

ROME, Sept. 27 (Xinhua) -- The 30th general assembly of the International Council for Science (ICSU) kicked off here on Tuesday to address key global challenges, featuring over 275 scientists and experts from all over the world.The goal of the four-day event, hosted for the first time in Rome by the National Research Center (CNR) as Italy's scientific member at ICSU, is to discuss how science can contribute to boosting sustainable development, fighting climate change, increasing well-being and health in the changing urban environment and tackling the side-effects of progress.At the official opening ceremony, CNR president Francesco Profumo stressed that scientific research was the key to solving all current crises."It's during times of crises that inventions, great strategies and discoveries are made," he said quoting Albert Einstein."Global cooperation is crucial in addressing society's needs. In the wake of the negative economic outlook we are witnessing research and technological transfer can turn into efficient instruments to guide countries towards a solid development giving us the tools to tackle with lucidity the great obstacles we face," observed Profumo.Appealing to both private and public institutions, Profumo thus urged to boost strategic partnerships between universities, governments and research centres."We must create a network of knowledge-sharing together with enterprises in order to multiply and better implement growth and well-being opportunities. But in order to do so concrete political decisions must be undertaken and financial resources are needed," he added.

BEIJING, Sept. 27 (Xinhuanet) -- Scientists have been making great efforts to show how harmful coffee is to us, though no evidence yet. A latest study may be reassuring for coffee-lovers.Women who drink caffeinated coffee are less likely to be depressed than those don't. And the more they drink, the lower risk of developing depression, according to a study published Monday in the Archives of Internal Medicine. Researchers of the study tracked the health of over 50,000 women aged between 30 and 55 in 1996 for a decade and recorded their mental health and coffee intake periodically.They find that women who drank two or three cups of coffee per day were 15 percent less likely than those who drank little or decaffeinated coffee to be depressed.And for those who drank four or more cups, the risk of developing depression reduced by 20 percent.The reason why coffee could protect depression is not clear. But the scientists from the Harvard University speculated that caffeine was the key player. More research is needed to show whether caffeine can ward off depression.It might be that not-depressed people tended to be more activated and the habit of coffee drinking just fit in their lifestyle.However, the depressed ones, who might suffer from sleeplessness, chose not to drink coffee because the caffeine might exacerbate it."There's no need to start drinking coffee," said Dr. Alberto Ascherio, the senior author of the study, "The message is that coffee is safe to drink, with no adverse effects. That's really all that can be said."